date:Jun 01, 2016
eceiving development milestones and sales milestones and royalty payments on sales, if approved.
CMPA is a condition which is believed to be difficult to diagnose and affects up to 2-3% infants and young children during thier developmental stages, the company stated.
DBV will use its proprietary Viaskin technology platform to develop a ready-to-use, standard atopy patch test.
In 2015, Nestl introduced the cow's milk-related symptom score (CoMiSS) awareness tool developed by international expe